Ribomic, Inc. (4591) AI Stock Analysis

• Market Cap: ¥5.22B
• Dividend Yield: N/A
• Average Volume (3M): 477.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: -100.00%
• EPS Growth: 7.60%
• Country: JP
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.67
• Shares Outstanding: 54,332,640
• 10 Day Avg. Volume: 531,790
• 30 Day Avg. Volume: 477,440
• PEG Ratio: 0.32
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 1880.02
• P/FCF Ratio: -3.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ¥110.00 ▲(46.67% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is primarily held down by weak financial performance driven by minimal revenue, large ongoing losses, and persistent cash burn despite a debt-free balance sheet. Technical conditions are a meaningful positive with the stock trading above major moving averages and showing positive momentum. Valuation is constrained by negative earnings and no dividend yield data.

Positive Factors

Debt-free balance sheet

A zero-debt capital structure materially lowers refinancing and interest risk, preserving strategic optionality over months. This durable strength gives management flexibility to raise capital on better terms, delay costly refinancing, or prioritize R&D/clinical spend without immediate debt servicing pressure.

Positive gross profit where revenue exists

Consistent positive gross margins when revenue occurs indicate viable unit economics for products/services. If management can scale sales or stabilize revenue, margins could support operating leverage and long-term profitability once fixed costs and R&D intensity are reduced or matched by recurring revenue.

Cash burn roughly tracks accounting losses

Cash outflows aligning with reported losses imply limited hidden cash leakage and more predictable funding needs. This transparency aids planning and indicates that reducing reported losses through cost control or revenue growth should translate directly into cash conservation over the next several quarters.

Negative Factors

Minimal, volatile revenue

Very low and inconsistent revenue prevents coverage of fixed costs and blocks scale economics. Structural reliance on irregular receipts undermines reproducible growth, forcing continued reliance on external funding and making sustainable margin expansion unlikely without clear commercialization progress.

Large persistent cash burn

Sustained billion-yen cash outflows erode reserves and create recurring financing needs. Persistently negative operating and free cash flow constrains strategic choices, risks dilution from future capital raises, and threatens continuity unless revenue materially improves or expense structure is permanently reduced.

Declining equity / capital erosion

Halving of shareholders' equity over several years signals accumulation of losses and possible dilution, weakening the balance sheet buffer. Reduced equity lowers resilience to setbacks and increases dependence on external funding, limiting the firm’s ability to invest or absorb operational shocks.

Ribomic, Inc. Business Overview & Revenue Model

Company Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

How the Company Makes Money

null

Ribomic, Inc. Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue is minimal/volatile (including zero in FY2024) while losses and cash burn remain large (FY2025 net loss ~¥1.02B; operating cash flow ~-¥1.0B; free cash flow ~-¥1.03B). The main offset is a debt-free balance sheet, though equity has declined materially over time, indicating ongoing capital erosion.

Income Statement

Revenue is small and volatile, including a drop to zero in FY2024 and only ~¥2.1M in FY2025, indicating limited commercial scale and/or dependence on irregular sources. Profitability is deeply negative across the period, with losses widening again in FY2025 (net loss ~¥1.02B) and extremely weak margins given the low revenue base. A positive is that reported gross profit is generally positive (where revenue exists), but operating costs overwhelm the business model at its current stage.

Balance Sheet

The company reports no debt across all years, which reduces financial risk and refinancing pressure. However, equity has declined materially over time (from ~¥6.0B in FY2021 to ~¥3.0B in FY2025), consistent with ongoing losses and dilution/erosion of capital. Returns on equity are persistently negative, highlighting that the balance sheet strength is being consumed rather than compounded.

Cash Flow

Cash burn is substantial and persistent, with operating cash flow negative every year (about -¥1.0B in FY2025) and free cash flow also negative (about -¥1.03B in FY2025). While free cash flow improved in FY2024 versus FY2023, it deteriorated again in FY2025, suggesting an uneven but ongoing funding requirement. A modest positive is that free cash flow roughly tracks net loss (cash burn not dramatically worse than accounting losses), but the absolute level of burn remains high versus the revenue base.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	607.00K	2.11M	0.00	65.97M	80.91M	91.96M
Gross Profit	173.00K	1.19M	-10.50M	0.00	0.00	0.00
EBITDA	-1.02B	-1.05B	-1.11B	-1.79B	-1.73B	-1.21B
Net Income	-992.53M	-1.02B	-1.02B	-1.65B	-1.68B	-1.19B
Balance Sheet
Total Assets	2.93B	3.19B	3.55B	4.58B	4.95B	6.12B
Cash, Cash Equivalents and Short-Term Investments	2.81B	3.04B	3.40B	4.33B	4.70B	5.84B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	111.84M	142.21M	155.81M	199.30M	260.53M	116.96M
Stockholders Equity	2.82B	3.04B	3.39B	4.38B	4.69B	6.00B
Cash Flow
Free Cash Flow	0.00	-1.03B	-955.48M	-1.73B	-1.51B	-1.15B
Operating Cash Flow	0.00	-996.97M	-932.76M	-1.71B	-1.50B	-1.15B
Investing Cash Flow	0.00	67.18M	177.27M	276.35M	689.56M	-1.70B
Financing Cash Flow	0.00	667.26M	27.65M	1.33B	354.72M	4.99B

Ribomic, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 75.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Positive. The current price of 75 is below the 20-day moving average (MA) of 90.65, below the 50-day MA of 87.34, and below the 200-day MA of 92.92, indicating a bullish trend. The MACD of 4.18 indicates Negative momentum. The RSI at 57.91 is Neutral, neither overbought nor oversold. The STOCH value of 37.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4591.

Ribomic, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4591	54 Neutral	¥5.22B	-4.17	―	―	-100.00%	7.60%
4571	52 Neutral	¥12.44B	-12.44	-26.70%	―	172.39%	8.27%
2183	52 Neutral	¥7.11B	-2.65	―	5.44%	-15.42%	-879.08%
4974	52 Neutral	¥138.12B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4575	51 Neutral	¥15.20B	-17.96	―	―	―	14.03%
4587	46 Neutral	¥171.31B	-100.54	-10.16%	―	-62.47%	-134.06%

Ribomic, Inc. Corporate Events

Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III

Ribomic reported Phase II trial results for its anti-FGF2 aptamer umedaptanib pegol in Japanese paediatric patients with achondroplasia, showing a statistically significant mean increase of 1.4 cm per year in annualized height velocity after 26 weeks of treatment. The study, which tested low- and high-dose regimens in 12 children and found mainly mild, short-term adverse events, supports proof-of-concept for the drug and underpins the company’s plan to seek approval to begin a pivotal Phase III trial.

Responses were observed in both dose cohorts, with notable height gains in several subjects and sustained improvements in a long-term extension, including benefits in some children previously treated with Voxzogo. While secondary endpoints showed no consistent efficacy trends, the favorable safety and primary endpoint data strengthen Ribomic’s position in the emerging achondroplasia treatment market and mark a key step toward potential commercialization of its lead aptamer therapy.

The most recent analyst rating on (JP:4591) stock is a Sell with a Yen82.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.

RIBOMIC Posts Continued Losses but Maintains Strong Equity Base in Nine-Month Results

RIBOMIC Inc. reported non-consolidated results for the nine months to December 31, 2025, with operating revenue effectively at zero and a net loss of ¥763 million, though the per-share loss narrowed from ¥18.88 to ¥15.86 year on year. Total assets rose to ¥3.38 billion and the equity ratio remained high at 94.2%, but the company continues to suspend dividends and forecasts a full-year loss of ¥1.28 billion on modest revenue of ¥3 million.

The biotech firm’s persistent losses underscore the long development timelines and funding demands typical of early-stage drug discovery companies, even as its strong equity ratio suggests a still-solid balance sheet. Shareholders face continued dilution risk, with issued shares rising to 54.3 million, and no near-term income returns, as management maintains a zero-dividend policy while prioritizing R&D and long-term pipeline value creation.

The most recent analyst rating on (JP:4591) stock is a Hold with a Yen83.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.

Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data

Ribomic has filed a new substance patent application in Japan for RBM-006, a highly active anti-autotaxin aptamer with a shorter chain length than existing candidates, and reported that the molecule significantly suppressed retinal hemorrhage in a mouse model of diabetic retinopathy. The data, generated in collaboration with the University of Tokyo, strengthen the intellectual property position around RBM-006 and underscore its potential as a mechanistically distinct alternative to anti-VEGF drugs, which fail to benefit more than half of diabetic retinopathy patients, with the company planning to pursue early commercialization through partnerships while confirming that funding for development is secured and its full-year earnings forecast remains unchanged.

The most recent analyst rating on (JP:4591) stock is a Hold with a Yen84.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.